Theralase Technologies Inc. (CVE:TLT – Get Free Report) hit a new 52-week low on Friday . The company traded as low as C$0.15 and last traded at C$0.16, with a volume of 66381 shares trading hands. The stock had previously closed at C$0.16.
Theralase Technologies Price Performance
The firm has a market cap of C$39.84 million, a price-to-earnings ratio of -8.61 and a beta of -0.45. The firm’s fifty day moving average is C$0.19 and its two-hundred day moving average is C$0.20. The company has a debt-to-equity ratio of 14.85, a current ratio of 1.91 and a quick ratio of 3.40.
Theralase Technologies Company Profile
Theralase Technologies Inc, a clinical stage pharmaceutical company, engages in the research and development of light activated photo dynamic compounds (PDCs) and their associated drug formulations to treat cancers, bacteria, and viruses in Canada, the United States, and internationally. It also designs, develops, manufactures, and markets patented and proprietary super-pulsed laser technology for the healing of chronic knee pain, as well as for off-label use to heal various nerve, muscle, and joint conditions.
Featured Articles
- Five stocks we like better than Theralase Technologies
- How to Capture the Benefits of Dividend Increases
- Rocket Lab’s Big Rebound? Analysts Suggest the Dip’s a Gift
- Mastering Discipline: Overcoming Emotional Challenges In Trading
- Meta’s AI Moment? New SAM 3 Model Has Wall Street Turning Bullish
- How to buy stock: A step-by-step guide for beginners
- Snowflake Stock: The Dip That Smart Investors Are Buying Right Now
Receive News & Ratings for Theralase Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theralase Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
